Page last updated: 2024-10-22

amlodipine and Dyslipidemia

amlodipine has been researched along with Dyslipidemia in 34 studies

Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.

Research Excerpts

ExcerptRelevanceReference
"We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia."9.69A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023)
"This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia."9.34A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020)
"Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies."9.30Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019)
"Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery."9.19[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014)
"This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function."9.15The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011)
"Early and sustained improvement in small artery compliance was observed following coadministration of amlodipine and atorvastatin, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia."9.14Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009)
" The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy."9.12A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007)
"The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia."9.12Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006)
"- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk."7.88EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018)
"We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)."7.76[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010)
" There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg."7.30Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023)
" The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up."6.94Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020)
" The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets."6.46Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010)
"We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia."5.69A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023)
"Hypertension and dyslipidemia are important risk factors for cardiovascular disease."5.56Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020)
"This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia."5.34A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020)
"Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies."5.30Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019)
"Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery."5.19[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014)
" In this study, we investigated the effects of valsartan and amlodipine on the lipid profile in patients with newly diagnosed essential hypertension."5.17An additional LDL-lowering effect of amlodipine; not only an antihypertensive? ( Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H, 2013)
"This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function."5.15The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011)
"Single-pill amlodipine/atorvastatin targets the two most common modifiable cardiovascular risk factors, hypertension and dyslipidaemia."5.14International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. ( Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009)
"The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia."5.14Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). ( Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009)
"Early and sustained improvement in small artery compliance was observed following coadministration of amlodipine and atorvastatin, thus demonstrating a vascular benefit with simultaneous treatment of hypertension and dyslipidemia."5.14Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009)
"The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia."5.12Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006)
" The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy."5.12A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007)
"- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk."3.88EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018)
"Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia."3.88[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018)
"the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks."3.81Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015)
"We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)."3.76[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010)
" There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg."3.30Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023)
" The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up."2.94Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020)
" The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals."2.76Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. ( Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S, 2011)
" The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets."2.46Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010)
"Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition."2.45Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. ( Bangalore, S; Devabhaktuni, M, 2009)
"Hypertension and dyslipidemia are important risk factors for cardiovascular disease."1.56Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020)
"5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification."1.51Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. ( Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019)
"Our objective was to describe prescribing patterns of simvastatin in combination with medications known to increase the risk of myopathies following updated product labeling dosing restrictions in June 2011."1.42Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. ( Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM, 2015)
"Cardiovascular diseases are the leading cause of death worldwide."1.39Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. ( Ivanovic, B; Tadic, M, 2013)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (29.41)29.6817
2010's18 (52.94)24.3611
2020's6 (17.65)2.80

Authors

AuthorsStudies
Kim, MC1
Ahn, Y2
Kim, MH2
Kim, SY3
Hong, TJ1
Rhee, MY3
Kim, SH1
Hong, SJ3
Kim, H2
Kim, W2
Chae, IH2
Kang, DH2
Kim, BK1
Kim, HS3
Jung, HW1
Kim, CY1
Hong, SP2
Bae, HJ1
Choi, JY1
Ryu, JK1
Lee, JB1
Lee, KH1
Han, KR1
Yang, DH1
Park, CG3
Yu, GW1
Park, SJ1
Hyon, MS3
Shin, JH3
Hong, BK1
Jin, HY1
Lee, SY1
Seol, SH1
Lee, SR1
Lee, KJ1
Cho, EJ4
Nam, CW1
Park, TH1
Kim, U2
Kim, KS1
Perrone, V1
Veronesi, C1
Gambera, M1
Nati, G1
Perone, F1
Tagliabue, PF1
Degli Esposti, L1
Volpe, M1
Sofogianni, A1
Tziomalos, K1
Chang, K2
Ahn, JC2
Yu, CW1
Cho, KI1
Kim, YJ1
Lee, SH2
Kim, SJ1
Ahn, YK1
Lee, CH1
Kim, M1
Lin, CP1
Tung, YC1
Hsiao, FC1
Yang, CH1
Kao, YW1
Lin, YS1
Chu, YC1
Chu, PH1
Jin, X1
Han, KH1
Sung, JH1
Cho, JM2
Lee, HC1
Choi, SY1
Lee, K1
Kim, WS1
Kim, JH2
Yoo, BS1
Lee, JH2
Kim, PJ1
Sung, KC1
Hwang, J1
Kwon, K1
Seo, JS1
Lee, H1
Cho, Y1
Tabukashvili, R1
Kapetivadze, V1
Tchaava, K1
Gegeshidze, N1
Lazashvili, T1
Maglapheridze, Z1
Jeong, HS1
Pyun, WB1
Kang, WC1
Naydenov Naydenov, S1
Margaritov Runev, N1
Ivanov Manov, E1
Georgieva Torbova-Gigova, S1
Ivanovic, B1
Tadic, M1
Sutradhar, S3
Yunis, C3
Westergaard, M1
Tuchscherer, RM1
Nair, K1
Ghushchyan, V1
Saseen, JJ1
Galeeva, ZM1
Galiavich, AS1
Setiawati, A1
Kalim, H1
Abdillah, A1
Ferket, BS1
Hunink, MG1
Khanji, M1
Agarwal, I1
Fleischmann, KE1
Petersen, SE1
Erdine, S1
Ro, YM1
Tse, HF1
Howes, LG1
Aguilar-Salinas, CA1
Chaves, H1
Guindy, R1
Chopra, P1
Moller, RA1
Schou, IM1
Cohn, JN1
Wilson, DJ1
Neutel, J1
Houston, M1
Weinberger, MH1
Grimm, R2
Smith, DH1
Sun, W2
Neutel, JM2
Bestermann, WH1
Dyess, EM1
Graff, A1
Kursun, A2
Richard Hobbs, FD1
Gensini, G2
John Mancini, GB1
Manolis, AJ2
Bauer, B2
Genest, J2
Feldman, RD1
Harvey, P3
Jenssen, TG2
da Silva, PM2
Devabhaktuni, M1
Bangalore, S1
Curran, MP1
Malik, M1
Lopatin, IuM1
Abrashkina, ED1
Shaalali, N1
Pakhrova, OA1
Shutemova, EA1
Nazarova, OA1
Yamamoto, K1
Ozaki, H1
Takayasu, K1
Akehi, N1
Fukui, S1
Sakai, A1
Kodama, M1
Shimonagata, T1
Kobayashi, K1
Ota, M1
Horiguchi, Y1
Ebisuno, S1
Katsube, Y1
Yamazaki, T1
Ohtsu, H1
Hori, M1
Oliver, S1
Jones, J1
Leonard, D1
Crabbe, A1
Delkhah, Y1
Nesbitt, S1
Delgado-Montero, A1
Zamorano, JL1
Arslan, Z1
Ay, SA1
Karaman, M1
Cakar, M1
Celik, T1
Balta, S1
Akhan, M1
Sarlak, H1
Arslan, E1
Demirbas, S1
Demirkol, S1
Bulucu, F1
Saglam, K1
Hobbs, FD1
Mancini, GB1
Böhler, S1
Feldman, R1
Metcalfe, M1
Blank, R1
Messerli, FH1
Bakris, GL1
Ferrera, D1
Houston, MC1
Petrella, RJ1
Flack, JM1
Lee, E1
Preston, RA1
Herfert, O1
Dykstra, G1
Jukema, JW1
Sun, F1
Gillen, D1
McKeage, K1
Siddiqui, MA1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension[NCT03103256]Phase 3106 participants (Actual)Interventional2017-05-17Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia[NCT03067688]Phase 3202 participants (Actual)Interventional2017-04-11Completed
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension[NCT03088254]Phase 3126 participants (Actual)Interventional2016-09-20Completed
Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538]Phase 40 participants (Actual)Interventional2017-09-01Withdrawn (stopped due to Insufficient funds)
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)[NCT00174304]Phase 41,120 participants Interventional2004-10-31Completed
An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)[NCT00330785]Phase 31,250 participants Interventional2004-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

5 reviews available for amlodipine and Dyslipidemia

ArticleYear
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases

2009
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
    Drugs, 2010, Volume: 70, Issue:2

    Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseas

2010
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:18

    Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dysl

2012
A single-pill combination of amlodipine besylate and atorvastatin calcium.
    Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:3

    Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blocker

2006
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2008, Volume: 8, Issue:1

    Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Disease

2008

Trials

17 trials available for amlodipine and Dyslipidemia

ArticleYear
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2023, Volume: 23, Issue:4

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid

2023
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
    Journal of clinical hypertension (Greenwich, Conn.), 2023, Volume: 25, Issue:9

    Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension

2023
A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
    Journal of clinical hypertension (Greenwich, Conn.), 2020, Volume: 22, Issue:2

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination;

2020
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
    Journal of clinical hypertension (Greenwich, Conn.), 2020, Volume: 22, Issue:10

    Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; D

2020
Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial.
    Clinical therapeutics, 2019, Volume: 41, Issue:2

    Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Double-Blind Me

2019
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
    Vascular health and risk management, 2014, Volume: 10

    Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases;

2014
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
    Terapevticheskii arkhiv, 2014, Volume: 86, Issue:9

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, D

2014
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Journal of human hypertension, 2009, Volume: 23, Issue:3

    Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardi

2009
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
    American journal of hypertension, 2009, Volume: 22, Issue:2

    Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemia

2009
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
    Journal of clinical hypertension (Greenwich, Conn.), 2009, Volume: 11, Issue:1

    Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug

2009
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A

2009
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A

2009
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A

2009
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
    European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A

2009
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
    Vascular health and risk management, 2010, May-06, Volume: 6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarker

2010
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:3

    Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte

2011
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
    Journal of clinical hypertension (Greenwich, Conn.), 2011, Volume: 13, Issue:8

    Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African Americ

2011
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2013, Volume: 35, Issue:6

    Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C

2013
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
    Journal of clinical hypertension (Greenwich, Conn.), 2006, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholest

2006
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
    Journal of clinical pharmacology, 2007, Volume: 47, Issue:12

    Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive A

2007

Other Studies

12 other studies available for amlodipine and Dyslipidemia

ArticleYear
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2019, Volume: 26, Issue:5

    Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; B

2019
Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?
    Journal of clinical hypertension (Greenwich, Conn.), 2020, Volume: 22, Issue:2

    Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Dyslipidemias; Humans; Hyp

2020
Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.
    Journal of clinical hypertension (Greenwich, Conn.), 2020, Volume: 22, Issue:10

    Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Therapy, Combination; Dys

2020
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
    Georgian medical news, 2018, Issue:282

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl

2018
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
    Acta clinica Croatica, 2018, Volume: 57, Issue:3

    Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol; Ch

2018
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:6

    Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combin

2013
Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:1

    Topics: Amlodipine; Calcium Channel Blockers; Comorbidity; Drug Interactions; Drug Labeling; Drug Prescripti

2015
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
    Acta medica Indonesiana, 2015, Volume: 47, Issue:3

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub

2015
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Heart (British Cardiac Society), 2017, Volume: 103, Issue:7

    Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com

2017
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
    Kardiologiia, 2010, Volume: 50, Issue:7

    Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic

2010
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
    Kardiologiia, 2010, Volume: 50, Issue:5

    Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity;

2010
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
    International journal of cardiology, 2006, Jun-16, Volume: 110, Issue:2

    Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiov

2006